<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111241</url>
  </required_header>
  <id_info>
    <org_study_id>2004/949</org_study_id>
    <nct_id>NCT00111241</nct_id>
  </id_info>
  <brief_title>Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors</brief_title>
  <official_title>Assessment of Knee Joint Articular Cartilage Volume Change, Bone Loss and Change in Body Composition in Women Treated With Anastrozole or Letrozole and Comparison With Untreated Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Monash University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many women with breast cancer are treated with a class of drugs called aromatase inhibitors
      (mainly letrozole or anastrozole), which lowers the amount of estrogen being produced in the
      body. Women on aromatase inhibitors appear to experience joint pains and arthralgia. The aim
      of this study is to determine whether the joint pains experienced by some women on aromatase
      inhibitors is associated with more defects in their cartilage, compared to women not
      receiving this therapy. Using the magnetic resonance imaging (MRI) technique, the knee joint
      will be examined to assess changes in cartilage volume over time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mechanism of increased bone loss and fracture risk is clearly related to the depletion of
      estrogen production in the bone. But why there is a higher rate of reporting arthralgia,
      fracture and joint pain amongst women on aromatase inhibitors is not understood.

      Using magnetic resonance imaging (MRI) to measure knee articular cartilage volume, we have
      demonstrated that post menopausal hormone therapy used for at least five years is associated
      with retention of articular cartilage in the knee, indicating that oestrogen may protect
      against the development of osteoarthritis in post menopausal women. Furthermore, we have
      recently observed that free testosterone is associated with loss of tibial cartilage, after
      taking into account age, body mass index, baseline tibial cartilage volume, tibial plateau
      area and total bone mineral content in healthy men. Whether an excess of testosterone to
      oestrogen as a consequence of aromatase inhibition has an adverse effect on articular
      cartilage volume warrants further investigation.

      This study will include non-hysterectomised women aged 40 to 65 years who have undergone
      breast surgery and then commenced on aromatase inhibitors within the preceding 12 weeks. The
      control group (which has been fully recruited) included non-hysterectomised, healthy women
      aged 40 to 65 years. A MRI of the dominant knee will be used to compare changes in knee
      articular volume over time. A MRI will be done at baseline and again at 2 years. Changes in
      knee articular volume is the primary outcome. We will also use this opportunity to compare
      menopausal symptoms (assessed using the Menopause Quality of Life (MENQOL)questionnaire)
      between women treated with aromatase inhibitors and those who are not. Well-being will also
      be assessed using the Psychological General Well-Being index.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Knee Cartilage Volume</measure>
    <time_frame>Baseline, two years</time_frame>
    <description>change in medial and lateral articular tibial cartilage volume over two years</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knee Subchondral Bone Expansion</measure>
    <time_frame>Baseline, Two years</time_frame>
    <description>change in subchondral bone expansion area over two years</description>
  </secondary_outcome>
  <enrollment type="Actual">115</enrollment>
  <condition>Arthralgia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aromatase inhibitors (letrozole, anastrozole)</intervention_name>
    <description>Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study</description>
    <other_name>no other names</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be informed of study by their treating physician and invited to
        participate and by community sample.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Group 1 :

          -  Aged 40 - 65

          -  Non-hysterectomised women who have undergone breast surgery

          -  Women on aromatase inhibitors within preceding 12 weeks

        Group 2 : control group

          -  Healthy, non-hysterectomised women aged 40-65 .

        Exclusion Criteria:

          -  Previous knee injury requiring non-weight bearing treatment for &gt; 24 hrs or surgery
             (including arthroscopy)

          -  Inability to complete the study (eg proposed relocation)

          -  Contraindication to undergoing an MRI including pacemaker, metal sutures, presence of
             shrapnel, iron filings in eye

          -  Claustrophobia

        Additional Exclusions for Group 1

          -  Treatment with tamoxifen for &gt; 8 weeks prior to commencement

          -  Knee pain lasting for &gt;24 hours in the last 5 years (prior to commencement on
             anastrozole or letrozole)

          -  Anastrazole or Letrozole therapy for &gt; 12 weeks
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Davis, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director Women's Health Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Women's Health Research Program, Monash University, The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>May 18, 2005</study_first_submitted>
  <study_first_submitted_qc>May 18, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2005</study_first_posted>
  <results_first_submitted>April 6, 2015</results_first_submitted>
  <results_first_submitted_qc>December 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 5, 2018</results_first_posted>
  <last_update_submitted>November 26, 2018</last_update_submitted>
  <last_update_submitted_qc>November 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Monash University</investigator_affiliation>
    <investigator_full_name>Professor Susan Davis</investigator_full_name>
    <investigator_title>Professor of Women's Health</investigator_title>
  </responsible_party>
  <keyword>bone fracture</keyword>
  <keyword>cartilage</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>breast cancer</keyword>
  <keyword>aromatase inhibitors</keyword>
  <keyword>knee articular cartilage volume</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Women With Breast Cancer</title>
          <description>women with hormone receptor positive ( HR+) breast cancer, prescribed an aromatase inhibitor (AI)</description>
        </group>
        <group group_id="P2">
          <title>Healthy Control Group</title>
          <description>healthy postmenopausal aged-matched controls from prior data base</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Women With Breast Cancer on Aromatase Inhibitor Therapy</title>
          <description>women with hormone receptor positive breast cancer prescribed an aromatase inhibitor</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>healthy postmenopausal aged-matched controls from prior data base</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="115"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Knee Cartilage Volume</title>
        <description>change in medial and lateral articular tibial cartilage volume over two years</description>
        <time_frame>Baseline, two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Women With Breast Cancer</title>
            <description>women recruited with HR+ breast cancer prescribed an AI</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>healthy postmenopausal aged-matched controls from prior data base</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Cartilage Volume</title>
          <description>change in medial and lateral articular tibial cartilage volume over two years</description>
          <units>mm³</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2042" spread="151"/>
                    <measurement group_id="O2" value="1971" spread="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Knee Subchondral Bone Expansion</title>
        <description>change in subchondral bone expansion area over two years</description>
        <time_frame>Baseline, Two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Women With Breast Cancer</title>
            <description>women with hormone receptor positive ( HR+) breast cancer, prescribed an aromatase inhibitor (AI)</description>
          </group>
          <group group_id="O2">
            <title>Healthy Control Group</title>
            <description>postmenopausal, nonhysterectomized, women not taking hormone replacement therapy,and with a body mass(BMI) between 20 and 37 kilograms per metre squared (kg/m2)</description>
          </group>
        </group_list>
        <measure>
          <title>Knee Subchondral Bone Expansion</title>
          <description>change in subchondral bone expansion area over two years</description>
          <units>mm²</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2020" spread="180"/>
                    <measurement group_id="O2" value="1992" spread="204"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline, 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Women With Breast Cancer</title>
          <description>Of 45 women recruited with HR+ breast cancer prescribed an AI, 30 women provided paired MRI data, including 1 woman who withdrew at 0.8years due to metastatic disease. 3 women did not have even a baseline MRI (2 gave no reason and one withdrew with joint pain), 2 had no follow-up MRI, one stopped her AI, 3 cited personal reasons, one withdrew due to cancer complications, 3 changed to tamoxifen, one was lost to follow up and one gave no reason for withdrawal.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>Of 70 women participating as controls, 8 had missing MRI data</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Menopausal Symptoms and Well-being were previously entered as Secondary Outcome Measures. Data not available to assess these outcomes.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Prof Susan Davis</name_or_title>
      <organization>Monash University</organization>
      <phone>+61399030827</phone>
      <email>susan.davis@monash.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

